ImmunoGenesis Backs STING Agonist IMGS-203 With Two New Studies
Houston – November 05, 2026 -- ImmunoGenesis has published two papers reporting nonclinical evidence that its STING agonist IMGS-203 remodels the tumor microenvironment and can be combined with the company's cytotoxic dual-specific PD-L1/PD-L2 antibody. The clinical-stage biotech plans to take IMGS-203 into clinical development first in recurrent glioblastoma (GBM).
IMGS-203 reduces immunosuppressive cells and improves survival in tumor models
Nonclinical studies show that local administration of IMGS-203 remodels the tumor microenvironment (TME) and reduces immunosuppressive myeloid cell populations. It also enhances T-cell activation and improves survival in tumor models.
GBM is a highly immunosuppressive, myeloid-rich tumor in which conventional immune checkpoint inhibitors have shown limited efficacy as monotherapy.